Product/Composition:- | Amoxycillin + Potassium Clavulanate Tablets |
---|---|
Strength:- | 500 mg/125 mg, 875 mg/125 mg, 2 g/125 mg |
Form:- | Tablets |
Reference Brands:- | Augmentin, Augmentin XR(US); Augmentin, Amoxiclav(EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Amoxicillin-clavulanate inhibits bacterial cell wall synthesis via amoxicillin and overcomes beta-lactamase enzymes with clavulanate, expanding antibacterial coverage. Benefits include broad-spectrum activity, effectiveness against resistant bacteria, rapid infection control, and use in respiratory, urinary, skin, and soft tissue infections, offering reliable, combination therapy when prescribed appropriately.
Amoxicillin Potassium + Clavulanate tablets are approved in both EU and US for treating bacterial infections. In the EU, brands like Augmentin are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval is based on extensive clinical data; generics are also available. Both regions require detailed dossiers, including clinical trial results and pharmacovigilance plans, for initial approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access for amoxicillin-clavulanate tablets, ensuring adherence to European and US standards for safe, effective antibacterial therapy.